Abcam, ab265068, Human NCOA2 (KAT13C) knockout HEK-293T cell line

Size: 2 x 1000000Cells / vial / 1000000Cells / vial
NCOA2 KO cell line available to order. KO validated by. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 5. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Form:LiquidSee storage information,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 5

Product details:
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-NCOA2, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Zygosity-Homozygous, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
KAT13C also known as NCOA2 functions as a transcriptional coactivator involved in nuclear receptor-mediated gene expression. It has a molecular mass of approximately 170 kDa. This protein localizes in the nucleus where it binds with nuclear receptors to enhance transcriptional programming. It is expressed in various tissues including the brain heart and liver indicating its involvement in a diverse range of cellular activities.
Biological function summary
KAT13C/NCOA2 serves as part of a larger protein complex that regulates the expression of target genes following ligand binding to nuclear receptors. It acts as a scaffold protein recruiting additional transcriptional machinery to ensure efficient transcriptional activation. This role is critical for the regulation of hormone-responsive genes and in metabolism cell proliferation and differentiation processes.
Pathways
KAT13C/NCOA2 plays a significant role in the steroid hormone receptor signaling pathway and the nuclear hormone receptor signaling pathway. It interacts with other proteins like p160 family members and the CREB-binding protein (CBP) facilitating coordinated gene expression involved in hormone response and metabolism. These interactions position KAT13C/NCOA2 as an important player in fine-tuning cellular responses to external hormonal signals.
KAT13C/NCOA2 associates with prostate cancer and acute myeloid leukemia. In prostate cancer its interaction with androgen receptor signaling enhances cell proliferation. Meanwhile KAT13C/NCOA2 amplifies gene expression involved in leukemia progression through its interaction with MLL fusion proteins which are implicated in the development of acute myeloid leukemia. These connections underline its role in disease states where abnormal signaling and transcriptional regulation occur.